Media OutReach
Bora Pharmaceuticals Exits Integration Phase with Sequentially-Improved Gross and Operating Margins
Positioned to Unlock M&A Value through U.S. Manufacturing Amidst Geopolitical Complexities and Specialty Portfolio
HONG KONG SAR – Media OutReach Newswire – 14 May 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for first quarter of 2025.
- Fueled by expanded capacity and new dosage forms, Bora’s CDMO business delivered a record high quarter, up 52.4% YoY and 3.0% QoQ.
- As part of Bora’s long-term strategic growth plan, the Company is moving forward with a phased investment of tens of thousands US dollars to unlock the untapped potential of Maple Grove facility. This build-out is designed to enhance capabilities in oral solid dose and sterile manufacturing, strengthening the ability to support customer demand and scale future programs.
- Pharma Sales revenues rose 82.0% YoY based on reported unaudited monthly sales, driven by strong performance from the vigabatrin franchise, which includes three dosage forms. Notably, VIGAFYDE captured over 70% share in the new patient segment.
- Due to the completion of Plymouth area decommissioning, consolidated revenues for 1Q25 was NT$4.48 billion, a NT$350 million reversal from the unaudited monthly disclosures, all of which was attributed to the pharma sales segment.
- Despite margin pressure from partial maintenance shutdowns at the Maryland sterile injectable site in early January and softening demand for generic product dexlansoprazole (DLS), product mix improvement from growing specialty portfolio lifted gross margin from the low of 4Q24 to 42.2% in 1Q25. Tech transfer for 6 Upsher-Smith generic products to cost-competitive sites within Bora network remains on track, with full transfer expected by year-end to support further margin recovery.
- EPS from continuing operations reached NT$26.54, reflecting NT$2.44 billion of net non-operating income from the divestment of Bora Biologics and recognition of losses of Tanvex Biopharm. However, the decommissioning of the Plymouth area negatively impacted EPS by NT$12.99, resulting in a reported EPS of NT$13.55. Share capital increased 0.4% during the quarter from employee stock option exercises and convertible bond conversions.
- DLS competitors began exiting the market in early 2Q25 due to supply chain hiccups, creating new opportunities for Bora to increase share and drive recovery momentum.
- The Group remains optimistic that its first quarter restructuring efforts will increase the long-term value of its recent acquisitions, including unlocking NT$600 million in capital in 2025. CDMO business growth will be further accelerated with strategic U.S.-based capability and capacity.
The closure of Plymouth area was completed ahead of schedule during the quarter and the area has thus been reclassified as discontinued operation in our quarterly financial statements altogether. From an operational standpoint, Bora has discontinued 15 products in the U.S. generics market along with the restructure, with an additional 6 products transferred to more cost-efficient manufacturing sites within the Group. On the financial side, discontinued operation resulted in a negative impact of approximately NT$1.34 billion, including overhead, inventory and equipment write-downs as well as severance-related expenses.
Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by over NT$5.0 billion cash on hand. At Maple Grove, 4 global pharmaceutical clients are currently in advanced discussions regarding CAPEX investments which we view as a strong validation of the site’s value and strategic fit. While the timeline for full deployment spans several years, we are approaching this expansion with operational discipline and commercial alignment to ensure its success over time.
On pharma sales side, Bora weathered softness in DLS demand in the first quarter but quickly gained market share as a competitor exited in early second quarter. Generic business rebounded in April, supported by strong sales from new 2024 launches including Potassium Chloride ER Tablets (KCL), and anti-angina drugs Diltiazem (DTC and DTS). This recovery underscores Bora’s agility and the resilience of the dual-engine strategy. Furthermore, we have successfully consolidated distribution network for specialty drugs. Bora expects its pediatric spasm product, VIGAFYDE (the 505(b)(2) oral solution), to extend its success in the new patient market into the switch segment in the very near future, supporting future margin and operational leverage expansion.
We continue executing on our goals to scale up, achieve more and integrate smarter, ensuring that both internal and external clients benefit from cost-efficient, regionally aligned manufacturing. By extending the strength of our dual-engine model, we believe Bora shall continue to create above-average total shareholder return.”
Global CDMO Operations
Global CDMO Operations (excluding internal orders) delivered record-high revenues of NT$1.90 billion in the first quarter, up 52.4% YoY and representing approximately 39% of total revenue. Including internal orders, CDMO revenue reached NT$2.89 billion. A total of 600 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 30%, demonstrating strong clientele and advantage of scale. Bora CDMO continues to be a trusted partner for biotech and pharmaceutical innovators.
- In 1Q25, the small molecule CDMO pipeline added US$123 million in potential orders and US$78 million in backlog, both marking historic highs.
- CAPEX progress across sites reached approximately 50%, focused on debottlenecks, efficiency improvement, capacity increase and infrastructure upgrade to align with client and product needs. Flex Pro line at the Maryland sterile injectable facility was completed ahead of schedule and is expected to begin operations in early Q3.
- Maple Grove launched its first CDMO project during the quarter and is currently negotiating with potential clients while evaluating CAPEX plans for differentiated dosage platforms. Overall, North American capacity transformation is progressing as planned.
- Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients. Bora and Tanvex are actively pursuing U.S.-based commercial-scale manufacturing orders with a comprehensive one-stop service model.
Pharma Sales Operations
Pharma Sales Operations revenue reached NT$2.93 billion, representing 82.0% YoY growth and contributing approximately 61% of total revenue based on unadjusted numbers.
- As the Upsher-Smith team continue to consolidate distributors for specialty drugs, we saw early signs of positive engagement from both market and payer channels at the end of the first quarter. Following the 2024 integration of TWi, Upsher-Smith and Pyros teams, Bora has established a focused pipeline in CNS specialty areas. The company expects to file its first self-developed 505(b)(2) submission for infantile spasms (Stiripentol) with the U.S. FDA by year-end, alongside other pipeline developments.
- Pediatric epilepsy and TSC-related rare diseases represent the first wave of Bora’s pharma sales transformation targets. In addition to reducing over-reliance on generics, high-value rare disease and specialty drugs benefit from strong regulatory and payer support in the specialty pharmacy channel. These markets are less competitive with stable price, and offer targeted access to patient populations, allowing for meaningful long-tail value creation.
Bora will host an English online earnings call at 7:00 a.m. Taiwan time on May 15, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:00 p.m. on May 16, 2025. Both events will cover the company’s Q1’25 financial and business results and outlook.
English Online Earnings Presentation Link: https://www.zucast.com/event/54SiM5il/subscribe/create
The 2025 Annual General Shareholders’ Meeting will be held on May 23 at the Tainan Guantian Industrial Marketing Center.
Bora will participate in the Jefferies Global Healthcare Conference in New York on June 4–5. For 1:1 meetings with management, please contact your Jefferies representative.
Q2 2025: Expected in the 3rd week of August 2025
Q3 2025: Expected in the 3rd week of November 2025
Q4 2025: Expected in the 2nd week of March 2026
Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracorpcdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Today’s biggest stars express individuality and confidence with natural diamonds
LOS ANGELES, US – Media OutReach Newswire – 6 February 2026 – At this year’s GRAMMY Awards, the Red Carpet sparkled with natural diamonds punctuating the looks of today’s most celebrated music artists.
Leading artists, performers and presenters showed up for music’s biggest night in diamond jewelry looks that spoke to creativity, individuality, glamour and power. From nominees Olivia Dean and Sabrina Carpenter to presenter Keltie Knight’s choices, natural diamonds expressed not only the timeless glamour and brilliance they’re known for, but their ability to amplify personal style. Natural diamonds were spotted in a range of tones from icy whites to deep whiskeys, and in settings from platinum to rose gold. Just as Hollywood stars are hitting the Red Carpet this year in Desert diamonds, the biggest new trend in natural diamonds, musical artists are experimenting with a bolder diamond palette, creating a more personality-driven red carpet.
Desert diamonds
Desert diamonds, ranging from warm whites to deep whiskeys, were spotted everywhere, including on presenter Keltie Knight, who opted for unique diamond and yellow gold hoops by RENNA, as well as a smattering of yellow gold, fancy-shaped diamond solitaire rings from the brand. Highlights also included power player J Balvin who chose a clean and classic tuxedo paired with a large cushion cut yellow diamond ring that added a nice balance to the traditionally masculine look.
Simple Drops
Simple drop earrings emerged as a quiet standout at the GRAMMYs, proving that restraint can be just as impactful as large statement pieces. Addison Rae and Madison Beer leaned into effortless glamour, choosing sleek diamond drops that framed the face with subtle movement and modern elegance. Billie Eilish brought her signature edge, using pared-back diamond drops to balance her bold black and white suiting. Kelsea Ballerini elevated the look in Sabyasachi, where refined diamond drops added softness and romance, while Reba McEntire turned to Martin Katz for timeless brilliance, opting for classic diamond drops that were sure to catch the eye.
Diamond Hoops for Men
Men are increasingly embracing minimalist yet impactful diamond hoop earrings as a refined accessory choice. Bad Bunny paired his sharp Schiaparelli tuxedo with a single diamond hoop earring, bringing a subtle but polished sparkle to his look that perfectly balanced his experimental sartorial vibe. Kaytranada’s red carpet presence and inclination for understated yet stylish accessories suggest that simple diamond hoops align naturally with his fashion-forward aesthetic. This trend points to a broader moment in men’s red carpet jewelry: pared-back diamond hoops that provide polished shine without overpowering the rest of the ensemble, signaling a move toward jewelry that feels personal, versatile, and modern.
Rings
Rings at the GRAMMYs reflected a dual trend of bold expression and refined delicacy, underscoring natural diamonds’ versatility. Sabrina Carpenter complimented her look in Chopard, opting for diamond rings that delivered impact without overpowering her look, while Sombr also made a striking impression with a diamond ring that was perfect high-jewelry shine to go with his existing sequined ensemble. In contrast, Olivia Dean showcased a more delicate approach in Cartier High Jewelry, layering elegant diamond rings that emphasized timeless sophistication perfectly echoing her Chanel gown. Miley Cyrus made perhaps the boldest ring statement of the night with several diamond rings stacked and worn over leather gloves.
Necklaces
Necklaces at the GRAMMYs showcased how natural diamonds can define both quiet refinement and bold presence on the red carpet. On the delicate end of the spectrum, Charlotte Lawrence in Messika exemplified understated luxury with a finely crafted diamond necklace that traced the neckline proving that less is more. In contrast, Hailey and Justin Bieber turned heads with matching Lorraine Schwartz statement diamond neck pieces that anchored their looks. Tate McRae also grabbed attention with a 50 carat Lorraine Schwartz necklace, while Pharrell Williams elevated his ensemble with a striking diamond necklace that blended artistry and scale. Together, these moments underscored a versatile necklace trend: from minimalist diamonds that whispered elegance to oversized, expressive pieces that commanded attention. Natural diamonds continue to serve as dynamic anchors in personal style storytelling.
Hashtag: #ADiamondisForever #NaturalDiamonds #diamonds #GRAMMYS
https://www.debeersgroup.com/
https://www.linkedin.com/company/debeersgroup/posts/?feedView=all
https://www.facebook.com/DeBeersGroupOfCompanies
https://www.instagram.com/debeersgroup/
The issuer is solely responsible for the content of this announcement.
About De Beers Group
Established in 1888, De Beers Group is the world’s leading diamond company with expertise in the exploration, mining, marketing and retailing of diamonds. Together with its joint venture partners, De Beers Group employs more than 20,000 people across the diamond pipeline and is the world’s largest diamond producer by value, with diamond mining operations in Botswana, Canada, Namibia and South Africa. Innovation sits at the heart of De Beers Group’s strategy as it develops a portfolio of offers that span the diamond value chain, including its jewellery houses, De Beers London and Forevermark, and other pioneering solutions such as diamond sourcing and traceability initiatives Tracr and GemFair. De Beers Group also provides leading services and technology to the diamond industry in the form of education and laboratory services and a wide range of diamond sorting, detection and classification technology services.
De Beers Group is committed to ‘Building Forever,’ a holistic and integrated approach to sustainability that underpins our efforts to create meaningful impact for the people and places where our diamonds are
discovered. Building Forever focuses on three key areas where, through collaborations and partnerships around the globe, we have an enhanced ability to drive positive impact; Livelihoods, Climate and Nature. De Beers Group is a member of the Anglo American plc group. For further information, visit www.debeersgroup.com.
Media OutReach
ICONSIAM Drives Its Destination Marketing Strategy to Elevate Bangkok as a Global Chinese New Year Destination
Featuring Renowned Actor Wang Zhuo Cheng and T-Pop Sensation BUS to Boost Thai–Chinese Tourism Economy
BANGKOK, THAILAND – Media OutReach Newswire – 5 February 2026 – ICONSIAM, the global landmark on the banks of the Chao Phraya River, announces a major collaboration with leading public and private partners—including the Ministry of Culture (Thailand), the Tourism Authority of Thailand (TAT), KASIKORNBANK, CP AXTRA “Makro – Lotus”, Alipay +, and Tiger Balm—to host a world-class Chinese New Year celebration. Reinforcing its Destination Marketing strategy, ICONSIAM aims to position itself as one of the world’s premier Chinese New Year destinations through festivities that blend Thailand’s cultural heritage with revered Chinese traditions. A key highlight is ICONSIAM’s spiritually significant location, known as the “Dragon’s Belly,” a powerful symbol of prosperity along the most beautiful curve of the Chao Phraya River. To honor the Year of the Horse, a sacred statue of Guan Yu—the deity of honesty, loyalty, and righteousness, will be enshrined. The celebration will feature world-class entertainment led by renowned Chinese actor Wang Zhuo Cheng and T-Pop Sensation BUS, alongside dragon and lion dances, festive street food, shopping, and cultural experiences. ICONSIAM is confident that foot traffic and spending within the destination will grow by more than 10%, helping to stimulate overall economic activity and tourism in the first quarter. The event will take place from 12–17 February 2026 at River Park, ICONSIAM.
Mrs. Suma Wongphan, Executive Vice President of ICONSIAM Co., Ltd. said “This event reaffirms ICONSIAM’s role as a Global Experiential Destination that captivates visitors worldwide. Our ambition is not only to elevate Thailand’s tourism experience, but also to celebrate the deep-rooted ties between Thailand and China. We have curated a landmark festival that seamlessly blends traditional beliefs with contemporary artistry, creating a special experience to attract global audiences to witness the most magnificent Chinese New Year celebration along the Chao Phraya River. Alongside the cultural aspects, ICONSIAM enhances the festive experience through its ‘Lucky Angpao Mega Campaign’, offering over 8,300 prizes, with expectations of driving more than 10% growth in visitor traffic and 10% increase in consumer spending during the campaign period.”
The 2026 Chinese New Year season is expected to generate significant economic impact across Thailand’s tourism sector, aligning closely with the Tourism Authority of Thailand’s strategy in setting the target of attracting 6.7 million Chinese visitors under ongoing visa-free measures. ICONSIAM is confident that the scale and creativity of this celebration will serve as a powerful catalyst in advancing Thailand’s tourism and retail sectors to global prominence.
The ICONSIAM A Prosperous Chinese New Year 2026 key highlights include:
- Landmark of Blessing: Visitors are invited to experience profound spiritual power at The Auspicious Guan Yu Shrine, featuring the enshrinement of five sacred manifestations of Guan Yu, brought directly from the People’s Republic of China for the first time in Thailand. Enhancing the experience is the Interactive Blessing Pavilion, showcasing the “Eight Auspicious Horses” through cutting-edge interactive technology that breathes new life into ancient mythology.
- Prosperous Celebration: The riverside comes alive with a world-class cultural spectacle led by the appearance of globally renowned Chinese actor Wang Zhuo Cheng, who joins the grand procession of the legendary ‘Long Ma’ (Dragon Horse), a mythical creature stretching over 32 metres in length, symbolising success and progress. The celebration is further energised by a breathtaking performance of the dragon-horse dance by Thailand’s leading T-POP sensation BUS (Because of You I Shine), creating a powerful fusion of tradition and contemporary pop culture.
- The Miracle of Fountain: At ICONSIAM’s iconic river curve — regarded as the most beautiful bend of the Chao Phraya, visitors will witness the mesmerising “Chao Phraya River Dragon Multimedia Water Feature,” the longest of its kind in Southeast Asia, featuring a choreographed spectacle of dancing fountains, light, and sound.
More than a celebration, ICONSIAM A PROSPEROUS CHINESE NEW YEAR 2026 is a cultural phenomenon that positions Bangkok as one of the world’s most compelling festive destinations. Be part of this extraordinary celebration from February 12–17, 2026, at River Park, ICONSIAM. Discover upcoming events and the latest updates via ICONSIAM’s Facebook at www.facebook.com/ICONSIAM or call 1338 for more information.
Hashtag: #ICONSIAMCNY2026 #ICONSIAMaProsperousChineseNewYear2026 #ICONSIAM
The issuer is solely responsible for the content of this announcement.
Media OutReach
DFI Retail Group to Announce 2025 Full Year Financial Results and Host Analyst Presentation Live Webcast
Time: 09:30-10:30 am (Hong Kong Time)
Hashtag: #DFIRetailGroup #Mannings #Guardian #7-Eleven #Wellcome #MarketPlace #IKEA #yuu
The issuer is solely responsible for the content of this announcement.
About DFI Retail Group
DFI Retail Group (the ‘Group’) is a leading Asian retailer, driven by its purpose to “Sustainably Serve Asia for Generations with Everyday Moments”.
At 1 December 2025, the Group and its associates operated over 7,400 outlets, and employed over 81,000 people across 12 markets.
The Group is dedicated to delivering quality, value and service to Asian consumers through a compelling retail experience, supported by an extensive store network and highly efficient supply chains.
The Group and its associates, operates a portfolio of well-known brands across five key divisions: health and beauty, convenience, food, home furnishings and restaurants.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn